论文部分内容阅读
目的探讨血清a-L岩藻糖苷酶(AFU)测定在糖尿病控制中的应用及临床意义。方法将糖尿病患者分为糖代谢控制组(血糖浓度≤7.8mmol/L)和糖代谢失控组(血糖浓度>7.8mmol/L),应用日立7170全自动生化分析仪,对82例糖尿病患者和90例正常对照人员血清AFU进行测定。结果糖尿病患者糖代谢失控组AFU测定结果显著高于正常对照组(P<0.01)及糖尿病患者糖代谢控制组(P<0.05);而在糖尿病患者控制组AFU测定结果和正常对照组之间无显著性差异(P>0.05)。结论血清a-L岩藻糖苷酶(AFU)在糖尿病糖代谢失控时明显偏高,可作为糖尿病观察治疗与血糖控制的临床指标。
Objective To investigate the clinical application of serum a-L fucosidase (AFU) in the control of diabetes. Methods Diabetic patients were divided into glucose metabolism control group (blood glucose concentration≤7.8mmol / L) and glucose metabolism uncontrolled group (blood glucose concentration> 7.8mmol / L). Hitachi 7170 automatic biochemical analyzer was used to analyze 82 patients with diabetes mellitus and 90 Cases of normal control serum AFU were measured. Results The results of AFU in control group with diabetes mellitus were significantly higher than those in control group (P <0.01) and glycometabolism control group (P <0.05). However, there was no significant difference between control group and control group Significant difference (P> 0.05). Conclusions Serum a-L fucosidase (AFU) is significantly higher in the uncontrolled glucose metabolism of diabetes mellitus, which may be used as a clinical indicator of diabetes mellitus and blood glucose control.